Infant growth outcomes after maternal tenofovir disoproxil fumarate use during pregnancy.

Published

Journal Article

To determine whether maternal use of tenofovir disoproxil fumarate for treatment of HIV in pregnancy predicts fetal and infant growth.The study population included HIV-uninfected live-born singleton infants of mothers enrolled in the International Maternal Pediatric Adolescent AIDS Clinical Trials Group protocol P1025 (born 2002-2011) in the United States and exposed in utero to a combined (triple or more) antiretroviral regimen. Infant weight at birth and 6 months was compared between infants exposed and unexposed to tenofovir in utero using 2-sample t test, χ test, and multivariable linear and logistic regression models, including demographic and maternal characteristics.Among 2025 infants with measured birth weight, there was no difference between those exposed (N = 630, 31%) versus unexposed to tenofovir in mean birth weight (2.75 vs. 2.77 kg, P = 0.64) or mean gestational age- and sex-adjusted birth weight z-score (WASZ) (0.14 vs. 0.14, P = 0.90). Among 1496 infants followed for 6 months, there was no difference in mean weight at 6 months between tenofovir-exposed (N = 457, 31%) and tenofovir-unexposed infants (7.64 vs. 7.59 kg, P = 0.52) or in mean WASZ (0.29 vs. 0.26, P = 0.61). Tenofovir exposure during the second/third trimester, relative to no exposure, significantly predicted underweight (WASZ < 5%) at age 6 months [odds ratio (95% confidence interval): 2.06 (1.01 to 3.95), P = 0.04]. Duration of tenofovir exposure did not predict neonatal or infant growth.By most measures, in utero exposure to tenofovir did not significantly predict infant birth weight or growth through 6 months of age.

Full Text

Duke Authors

Cited Authors

  • Ransom, CE; Huo, Y; Patel, K; Scott, GB; Watts, HD; Williams, P; Siberry, GK; Livingston, EG; P1025 Team of the International Maternal Pediatric Adolescent AIDS Clinical Trials Group,

Published Date

  • December 2013

Published In

Volume / Issue

  • 64 / 4

Start / End Page

  • 374 - 381

PubMed ID

  • 24169122

Pubmed Central ID

  • 24169122

Electronic International Standard Serial Number (EISSN)

  • 1944-7884

International Standard Serial Number (ISSN)

  • 1525-4135

Digital Object Identifier (DOI)

  • 10.1097/QAI.0b013e3182a7adb2

Language

  • eng